Gsa Capital Partners LLP Madrigal Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$231.06 - $307.08 $748,634 - $994,939	3,240 New	3,240 $784,000
Q1 2022 May 11, 2022	SELL	$55.89 - $101.89 $267,154 - $487,034	-4,780 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$72.34 - $95.09 $316,559 - $416,113	-4,376 Reduced 47.79%	4,780 $405,000
Q3 2021 Nov 12, 2021	BUY	$78.35 - $105.02 $325,387 - $436,148	4,153 Added 83.01%	9,156 $731,000
Q2 2021 Aug 05, 2021	BUY	$97.2 - $137.59 $486,291 - $688,362	5,003 New	5,003 $487,000
Q1 2021 May 10, 2021	SELL	$108.54 - $125.2 $361,872 - $417,416	-3,334 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$110.06 - $133.7 $366,940 - $445,755	3,334 New	3,334 $371,000
Q1 2020 May 12, 2020	SELL	$66.76 - $93.49 $817,209 - $1.14 Million	-12,241 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$84.28 - $118.5 $721,773 - $1.01 Million	8,564 Added 232.91%	12,241 $1.12 Million
Q3 2019 Nov 12, 2019	BUY	$84.4 - $106.53 $310,338 - $391,710	3,677 New	3,677 $317,000
Q3 2018 Nov 13, 2018	SELL	$207.3 - $300.31 $352,824 - $511,127	-1,702 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$101.55 - $313.9 $172,838 - $534,257	1,702 New	1,702 $476,000

335

22.3M

960K

940K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.75B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.